Leptomeningeal disease in oligodendroglial tumors: a population-based study

J Neurooncol. 2011 Sep;104(3):811-5. doi: 10.1007/s11060-011-0551-3. Epub 2011 Mar 4.

Abstract

In this population-based study, we determined the frequency and clinical characteristics of leptomeningeal disease (LMD) developing in the context of oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas). LMD occurred in only 3.9% (8/204) of oligodendroglial tumors and in patients with more recurrences [mean 2.88 vs. 1.27 in LMD and non-LMD, respectively (p = 0.001)]. In contrast to LMD from systemic solid tumors, the median survival following the diagnosis of LMD in oligodendroglial tumors was surprisingly long at 22 months (95% CI 11-33 months). Treatment with oral chemotherapy seemed as effective as more aggressive treatments (e.g. repeat RT or intrathecal chemotherapy) in these patients.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Brain Neoplasms / epidemiology*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / mortality
  • Chromosome Aberrations*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 1 / genetics*
  • Community Health Planning
  • Disease Progression
  • Female
  • Humans
  • Karnofsky Performance Status
  • Male
  • Meninges / pathology*
  • Middle Aged
  • Oligodendroglioma / epidemiology*
  • Oligodendroglioma / genetics
  • Oligodendroglioma / mortality
  • Retrospective Studies
  • Young Adult